|
Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL). |
| |
|
Honoraria - Abbvie; AstraZeneca; BeiGene; BMS; Janssen; Novartis Canada Pharmaceuticals Inc; Roche/Genentech |
Consulting or Advisory Role - Roche Canada |
Research Funding - Astex Pharmaceuticals (Inst); BeiGene (Inst); Celgene/Bristol-Myers Squibb (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Roche Canada (Inst); Shattuck Labs (Inst); Takeda (Inst) |
| |
|
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Kite/Gilead; Loxo/Lilly; Novartis; nurix; Roche/Genentech |
Research Funding - Amgen; AstraZeneca; Merck; MustangBio |
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia. |
Travel, Accommodations, Expenses - AstraZeneca; Kite/Gilead; Roche/Genentech |
| |
|
Honoraria - Adaptive Biotechnologies; Lilly |
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Adicet Bio; Allogene Therapeutics; AstraZeneca; BMSi; Cellectar; Genmab; Janssen; Kite/Gilead; Novartis; TeneoBio |
Speakers' Bureau - Epizyme |
Research Funding - Adaptive Biotechnologies; AstraZeneca; Merck (Inst) |
| |
|
Stock and Other Ownership Interests - Gilead Sciences; OverT Therapeutics |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Genmab; Janssen; Merck; MorphoSys; Regeneron; Seagen |
Research Funding - Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); FATE Therapeutics (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst) |
Expert Testimony - Jim Harmon |
| |
|
Honoraria - Cancer Network; Clinical Care Options; DAVA Pharmaceuticals; Onc Live |
Consulting or Advisory Role - Janssen |
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche; Genmab/Seattle Genetics; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company |
| |
|
Consulting or Advisory Role - Abbvie/Pharmacyclics; ADC Therapeutics; Ascentage Pharma; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Incyte; Janssen Oncology; Kite, a Gilead company; lava therapeutics; Loxo/Lilly; Novartis; Novartis; Roche/Genentech; Seagen; Syncopation Life Sciences |
Speakers' Bureau - AstraZeneca |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Morphosys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Blue Cross and Blue Shield of Rhode Island; Bristol-Myers Squibb; Genmab; Schrodinger |
Research Funding - Artiva (Inst); Genentech/Roche (Inst); Genmab (Inst); Kymera (Inst); Kymera (Inst); Pfizer (Inst); Precision Biosciences (Inst) |
| |
|
Research Funding - ADC Therapeutics; NCI |
Patents, Royalties, Other Intellectual Property - Stanford- Royalties |
| |
|
Stock and Other Ownership Interests - WITTY HEALTH |
Consulting or Advisory Role - AstraZeneca; BeiGene; Gilead Sciences; Incyte; Incyte; Kyowa Kirin International; Novartis; Pharmacyclics; Roche/Genentech; Seagen; TG Therapeutics |
Speakers' Bureau - Adaptive Biotechnologies; BeiGene; Epizyme; Gilead Sciences; Incyte; Kite, a Gilead company; Kyowa Kirin International; Seagen |
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Aileron Therapeutics (Inst); Artiva (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); I-Mab (Inst); incyte (Inst); Innate Pharma (Inst); Juno Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pharmacyclics/Janssen (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - ADC Therapeutics; ADC Therapeutics (I); AstraZeneca; AstraZeneca (I); Daiichi Sankyo; Daiichi Sankyo (I); Genentech; Genentech (I); Genmab; Genmab (I); Seagen; Seagen (I) |
Speakers' Bureau - BeiGene |
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Genentech (Inst); Genmab (Inst); Karyopharm Therapeutics (Inst) |
| |
|
Honoraria - ADC Therapeutics; Janssen Biotech; Janssen Biotech; Millennium; Sanofi |
Consulting or Advisory Role - Millennium; Sanofi |
Speakers' Bureau - Onclive |
Research Funding - Genentech/Roche (Inst) |
| |
|
Consulting or Advisory Role - Abbvie; BeiGene; Coherus Biosciences (I); Genentech; Incyte; Kite, a Gilead company; Lumanity; Numab |
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Ayala Pharmaceuticals (I); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (I); Denovo Biopharma (Inst); Enterome (Inst); Genentech (Inst); Ignyta (I); Incyte (Inst); Kymera (Inst); Merck (Inst); MorphoSys/Incyte (Inst); Nanjing (Inst); Viracta Therapeutics (Inst) |
| |
|
|
Stock and Other Ownership Interests - Genentech |
| |
|
Employment - Roche Canada |
| |
|
|
Stock and Other Ownership Interests - Roche |
| |
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Moderna Therapeutics; Regeneron; Roche |
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Bristol-Myers Squibb; Genentech; Karyopharm Therapeutics; Kite, a Gilead Company; Seagen; TG Therapeutics; Treeline Biosciences |
Research Funding - Autolus; Epizyme; Roche; Vincerx Pharma |
| |
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Patents, Royalties, Other Intellectual Property - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
| |
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
Travel, Accommodations, Expenses - Roche/Genentech |
| |
|
No Relationships to Disclose |